OrthoPediatrics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mathew Blackman from TD Cowen maintained a Buy rating on the stock and has a $23.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mathew Blackman has given his Buy rating due to a combination of factors including the company’s solid fourth-quarter performance and an encouraging free cash flow inflection. He notes that revenue came in slightly better than what was initially signaled and ahead of market expectations, while free cash flow turned positive and exceeded the earlier pre-announced range, indicating meaningful improvement in cash utilization.
He also emphasizes that management reaffirmed its 2026 outlook, which he views as achievable and potentially conservative given ongoing strength in core product lines and upcoming launches. Coupled with what he sees as an undemanding valuation and the transition to a free cash flow neutral or positive profile, he concludes that the shares have attractive upside potential relative to current levels.
In another report released today, Needham also maintained a Buy rating on the stock with a $30.00 price target.